# Legend Biotech Corp: Form 20-F for the period ended Dec 31, 2025

- Company: [Legend Biotech Corp](/companies/legn.md) (CIK 1801198)
- Form: 20-F
- Filed: 2026-03-10
- Accepted by EDGAR: Mar 10, 2026, 11:45 ET
- Period: 2025-12-31
- Accession: 0001801198-26-000008
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2025-01-01 to 2025-12-31 | $1.03bn | ifrs-full:RevenueFromContractsWithCustomers |
| Cost of revenue | 12 months, 2025-01-01 to 2025-12-31 | $397.1m | ifrs-full:CostOfSales |
| Operating income | 12 months, 2025-01-01 to 2025-12-31 | −$136.5m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2025-01-01 to 2025-12-31 | $14.2m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2025-01-01 to 2025-12-31 | −$296.8m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2025-01-01 to 2025-12-31 | −$0.81 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2025-01-01 to 2025-12-31 | −$0.81 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2025-01-01 to 2025-12-31 | −$100.2m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2025-01-01 to 2025-12-31 | $28.6m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2025-12-31 | $901.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2025-12-31 | $1.25bn | ifrs-full:CurrentAssets |
| Total assets | at 2025-12-31 | $1.73bn | ifrs-full:Assets |
| Current liabilities | at 2025-12-31 | $636.4m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2025-12-31 | $731.6m | ifrs-full:Liabilities |
| Shareholders' equity | at 2025-12-31 | $1.00bn | ifrs-full:Equity |
| Shares outstanding | at 2025-12-31 | 369,886,369 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm

Filed Mar 10, 2026.
Source: SEC EDGAR, the filing index for accession 0001801198-26-000008. Last ingested by Listed: Nov 10, 2026, 16:50 ET. No prices; not investment advice.
